Effects of ipragliflozin on glycemic control, appetite and its related hormones: A prospective, multicenter, open-label study (SOAR-KOBE Study).

Hiroshi MiuraKazuhiko Sakaguchi Yuko OkadaTomoko YamadaNatsu Otowa-SuematsuAnna SoHisako KomadaYushi HirotaTakeshi OharaYasuo KurokiKenta HaraTomokazu MatsudaMinoru KishiAkihiko TakedaKazuki YokotaYoshikazu Tamori Wataru Ogawa

Published in: Journal of diabetes investigation (2019)

The present results suggest that ipragliflozin improved glycemic control and reduced bodyweight, but also reduced serum leptin levels and might thereby have increased appetite.

Keyphrases

glycemic control
type diabetes
weight loss
blood glucose
open label
clinical trial
squamous cell carcinoma
adipose tissue
cross sectional